Cerebrospinal fluid synaptic biomarkers are elevated even in the preclinical stage of Alzheimer’s disease

Takeaway

  • Cerebrospinal fluid synaptic biomarkers are elevated in early preclinical Alzheimer's disease, even if amyloid-β pathology burden is low.

Why this matters

    This novel study reveals that cerebrospinal fluid synaptic biomarkers are increased early in the preclinical stage of the Alzheimer’s continuum. These biomarkers will enable the identification of preclinical Alzheimer’s disease which would allow timely intervention and better outcomes.